Prostate cancer incidence is sensitive to screening practices, however the impact of recent screening recommendations from the United States Preventative Services Task Force on prostate cancer incidence by age, stage, race, and Gleason score is unknown.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This study described the timing and magnitude of changes in prostate cancer incidence trends in the United States by month of diagnosis, and evaluated trends by age, Gleason score, and stage at diagnosis. We analyzed prostate cancer incidence trends using Surveillance, Epidemiology, and End Results (SEER) program data for men diagnosed with invasive prostate cancer from 2007 through 2012. JoinPoint analysis was used to detect changes in the rate of annual percent change (APC) in prostate cancer incidence for all diagnoses and by age, Gleason score, race, and stage. Prostate cancer incidence declined at an estimated -19. 6% APC beginning May 2011. This decline was observed in all age groups. Low-grade tumors (Gleason score ≤6) showed a steeper decline (-29. 1% APC) than high-grade tumors (Gleason score 8-10: -10. 8% APC). Only stage I/II and stage III tumors saw declines (-24. 2% and -16. 7% APC, respectively). A sharp decline in prostate cancer incidence began before release of the United States Preventative Services Task Force October 2011 draft and May 2012 final screening recommendation. The greatest change occurred with incidence of low-grade tumors, although there is concern that some high-grade tumors may now go undetected.
Cancer medicine. 2015 Dec 02 [Epub ahead of print]
Kimberly A Herget, Darshan P Patel, Heidi A Hanson, Carol Sweeney, William T Lowrance
Utah Cancer Registry, University of Utah, Salt Lake City, Utah. , Division of Urology, Department of Surgery, University of Utah, Salt Lake City, Utah. , Huntsman Cancer Institute, Salt Lake City, Utah. , Utah Cancer Registry, University of Utah, Salt Lake City, Utah. , Division of Urology, Department of Surgery, University of Utah, Salt Lake City, Utah.